Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
https://www.zacks.com/commentary/2255375/top-analyst-reports-for-microsoft-novo-nordisk-united-parcel?cid=CS-ZC-FT-research_daily-2255375
Apr 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
0
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
https://www.zacks.com/stock/news/2253502/moderna-mrna-up-6-on-upbeat-data-from-cancer-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253502
Apr 10, 2024 - Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
0
Company News for Apr 10, 2024
https://www.zacks.com/stock/news/2253234/company-news-for-apr-10-2024?cid=CS-ZC-FT-corporate_summary-2253234
Apr 10, 2024 - Companies in The News Are: MRNA, MRK, COIN, BN, NEOG
0
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
https://www.zacks.com/stock/news/2252285/merck-mrk-begins-phase-ii-ii-ovarian-cancer-study-on-adc-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252285
Apr 08, 2024 - Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
0
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526
Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
0
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2248395/why-merck-mrk-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2248395
Apr 01, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Merck (MRK) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2247735/merck-mrk-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2247735
Mar 28, 2024 - Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.
0
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400
Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2247337/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2247337
Mar 28, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
https://www.zacks.com/stock/news/2245870/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2245870
Mar 26, 2024 - Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
0
Page 1>